FDA Watch: Scientists Ask Agency to Rescind Approval for Opioid Management Test
Experts—including those in genetics and device regulation—say the AvertD assay did not predict risks of abuse ‘any better than chance’
Keep up to date on new and emerging diagnostic tests, testing trends and opportunities, and disruptive technologies
Experts—including those in genetics and device regulation—say the AvertD assay did not predict risks of abuse ‘any better than chance’
Several methods are being developed that improve the ability to rapidly identify organisms and report susceptibility results.
First marketing authorization of a blood test assessing genetic variants related to cancer opens the door for clearance of similar tests.
A brief overview of antimicrobial susceptibility testing, current methods used, and new methods on the horizon.
Polygenic risk scores may offer new screening and risk stratification options for cardiovascular disease—but how valuable are they?
Lisa-Jean Clifford of Gestalt Diagnostics, discusses key trends, challenges, and solutions in data analytics for clinical labs.
A pandemic-related drop in cancer diagnoses could spell long-term trouble for patients and providers.
Artificial intelligence models have a valuable role to play in each phase of the total testing process.
Genomic epidemiology can provide insights into pathogen transmission and evolution—and facilitate better countermeasures against infectious disease.
Approval for OTC use of a urine drug test that can be performed by non-CLIA facilities could help expand accessibility, expert says.
Patients’ unfettered access to complex test results can lead to confusion and distress—but generative AI can help.